Clinical Trials
14 trialsNCT07495124 2026-05-26
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
University of Washington
Phase 2 Not yet recruiting
NCT07604766 2026-05-22
RAINFOL-02
Genmab
Phase 3 Not yet recruiting
NCT07591831 2026-05-18
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07265739 2026-05-06
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
Massachusetts General Hospital
Phase 2 Not yet recruiting
NCT07545460 2026-04-22
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07489300 2026-03-24
BACON
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT07432594 2026-02-25
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07362147 2026-01-23
Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life
Taipei Veterans General Hospital, Taiwan
Phase NA Not yet recruiting
NCT07044349 2025-06-30
Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Not yet recruiting
NCT06602063 2025-06-27
Surgery for Relapsed Ovarian Cancer in Precision
Shanghai Gynecologic Oncology Group
Phase 1/2 Not yet recruiting
NCT06846424 2025-02-26
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Shanghai Gynecologic Oncology Group
Phase 1 Not yet recruiting
NCT06751485 2024-12-31
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Not yet recruiting
NCT06063070 2023-10-02
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT04515602 2020-08-27
FOCUS
Shanghai Gynecologic Oncology Group
Phase 3 Not yet recruiting